Compare DexCom, Inc. (DXCM) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Monster Beverage Corp — how do they compare? DexCom, Inc. trades at $78.49 (market cap $28.06B), while Monster Beverage Corp trades at $99.56 (market cap $95.42B). The key difference: Monster Beverage Corp is far larger — about 3.4× DexCom, Inc.'s market cap, and Monster Beverage Corp is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | MNST | |
|---|---|---|
Market Cap | $28.06B | $95.42B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $98.01 |
52-Week Low | $54.84 | $58.65 |
Enterprise Value | $27.03B | $93.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Monster Beverage (MNST) trades at $98.005, up 0.96% on the day, with a bullish technical signal and strong fundamental performance. The company has consistently beaten earnings expectations for the last three quarters, with Q1 2026 EPS of $0.58 beating estimates of $0.527. Revenue growth is robust, increasing from $6.3B in 2022 to $8.3B in 2025, while net profit margins have expanded to 23.11%. A 2-for-1 stock split was recently announced, effective August 11, 2026.
The outlook remains positive driven by international expansion and product innovation, with 45% of sales now from overseas. Key risks include premium valuation multiples (P/E of 47.14) and competitive pressure in the energy drink sector. Analyst consensus is 'Buy' with a $94.60 price target, though the current price trades slightly above this target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
